Rajesh Malik - Sep 13, 2022 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Medical Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Sep 13, 2022
Transactions value $
-$275,726
Form type
4
Date filed
9/16/2022, 04:31 PM
Previous filing
Jul 6, 2022
Next filing
Nov 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $7.02K +18K +24.59% $0.39* 91.2K Sep 13, 2022 Direct
transaction GTHX Common Stock Sale -$283K -18K -19.74% $15.71* 73.2K Sep 13, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -18K -45.64% $0.00 21.4K Sep 13, 2022 Common Stock 18K $0.39 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $15.38 and a high of $16.20. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 Represents (i) 54,332 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F4 All shares underlying this option have vested.